The following portion of the Investor Presentation is filed with this Current Report: the information on page 28 of the Investor Presentation regarding the
Companys anticipated timing of the availability of data from the Companys planned pivotal Phase 3 clinical trial of SPR994 and the Companys planned Phase 1 clinical trials of SPR206 and SPR720.
Forward-looking Statements
This report, including
the exhibits hereto, contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, development plans, regulatory activities, anticipated milestones, including the anticipated
timing of the availability of data from the Companys planned clinical trials in SPR994, SPR206 and SPR720, product candidate benefits, competitive position, business strategies, objectives of management, potential growth opportunities,
potential market size, possible or assumed future results of operations, projected costs and use of proceeds. In some cases, forward-looking statements can be identified by terms such as may, will, should,
expect, plan, aim, anticipate, could, intent, target, project, contemplate, believe, estimate, predict,
potential or continue or the negative of these terms or other similar expressions. All statements other than statements of historical facts contained in this report, including the exhibits hereto, are forward-looking
statements. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these
forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Companys product candidates, including
adverse results in the Companys clinical development processes; whether results from one clinical trial will be predictive of the results of future trials and whether preliminary data from the Companys clinical trials will be predictive
of final results from such trials; decisions made by the U.S. Food and Drug Administration and other regulatory authorities with respect to the development and commercialization of the Companys products; availability of funding sufficient for
the Companys foreseeable and unforeseeable operating expenses and capital expenditure requirements; the Companys ability to obtain, maintain and enforce intellectual property and other proprietary rights for its product candidates; the
Companys ability to implement its strategic plans; and other factors discussed in the Risk Factors section of the Companys periodic reports filed with the Securities and Exchange Commission, and risks described in other
filings the Company may make with the Securities and Exchange Commission in the future. The forward-looking statements included in this report, including the exhibits hereto, represent the Companys views as of the date of this report. The
Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do
so. These forward-looking statements should not be relied upon as representing the Companys views as of any date subsequent to the date of this report.